Skip to main content

Table 2 Bone marrow cell characteristics measured by fluorescence-activated cell sorting analysis

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

In vitro pravastatin treated cells
 Bone marrow samples DMEM (n = 10) Pravastatin (n = 10)
 Granulocytes 31.5 ± 2.6 30.8 ± 2.2
 Lymphocytes 37.4 ± 2.6 38.6 ± 2.5
 Monocytes 10.3 ± 1.9 10.9 ± 1.9
 Stromal cells 7.9 ± 3.6 7.5 ± 3.5
 Viability 96.6 ± 3.4 97.0 ± 2.5
Systemic in vivo pravastatin treatment recipients
 Bone marrow samples CKD (n = 6) CKD + pravastatin (n = 5)
 Granulocytes 23.6 ± 1.5 23.8 ± 1.3
 Lymphocytes 31.76 ± 2.8 31.8 ± 2.5
 Monocytes 21.3 ± 0.77 16.9 ± 1.3*
 Stromal cells 6.04 ± 0.4 7.76 ± 0.50*
 Viability 96.8 ± 0.4 97.7 ± 0.01*
  1. Data presented as mean ± standard deviation. CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium. *P <0.05 versus CKD.